Related Experiment Video
Updated: Feb 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai
N Kaewboonlert1, W Thitisopee2, W Sirintronsopon3
1School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand.
Insights
Genetic variations in SLCO1B1 (solute carrier organic anion transporter family member 1B1) did not predict simvastatin
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Molecular Biology
Background:
- SLCO1B1 gene polymorphisms are known to influence statin therapy response.
- Previous studies show inconsistent associations between SLCO1B1 variants and lipid-lowering effects.
Purpose of the Study:
- To examine the impact of SLCO1B1 c.388A>G, c.521T>C, and g.89595T>C polymorphisms on simvastatin's lipid-lowering efficacy.
- The study focused on Thai patients with hypercholesterolemia.
Main Methods:
- Genotyping of SLCO1B1 polymorphisms (c.388A>G, c.521T>C, g.89595T>C) using PCR-HRM.
- Analysis of serum lipid profiles (TC, TG, LDL-C, HDL-C) in 391 hypercholesterolemic patients before and after 3 or 12 months of simvastatin treatment (20-40 mg/day).
Main Results:
- Simvastatin significantly reduced TC, TG, and LDL-C levels after 3 and 12 months (P < .05).
- No significant changes in HDL-C levels were observed.
- No association was found between the studied SLCO1B1 polymorphisms and the lipid-lowering response to simvastatin.
Conclusions:
- The investigated SLCO1B1 polymorphisms (c.388A>G, c.521T>C, g.89595T>C) are unlikely to serve as reliable genetic markers for predicting simvastatin response in Thai hypercholesterolemic patients.
What Is Known:
SLCO1B1 polymorphisms have been reported to affect the responses to statin therapy. However, the association of these polymorphisms and lipid-lowering responses has been inconsistent.
Objective:
To investigate the effect of SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms on the lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
Methods:
Three hundred and 91 hypercholesterolaemic patients in Southern Thailand were enrolled and treated with simvastatin 20 or 40 mg per day. Among them, 191 and 200 patients were treated for 3 and 12 months, respectively. Serum lipids were measured before and after the treatment. SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms were analysed using polymerase chain reaction-high-resolution melting (PCR-HRM).
Results:
The allele frequencies of the SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms in Thai hypercholesterolaemic patients were 74.9%, 11.8% and 37.2%, respectively. After treatment with 20-40 mg simvastatin daily for 3 and 12 months, TC, TG and LDL-C concentrations were significantly lower than at baseline (P < .05). However, there was no a significant change in serum HDL-C after simvastatin treatment for 3 and 12 months (P > .05). Moreover, there was no association between SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms and lipid-lowering response to 3 and 12 months of either 20 or 40 mg/day simvastatin treatment.
What Is New And Conclusion:
SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms may not be useful as genetic markers of lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
04:51Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Vapor Pressure Lowering
What are Lipids?
Structure of Lipids
Lipid Digestion
Single Nucleotide Polymorphisms-SNPs